PHM 350 EXAM 1 QUESTIONS WITH CORRECT ANSWERS

PHM 350 EXAM 1 QUESTIONS WITH
CORRECT ANSWERS

If |the |volume |of |distribution |of |a |drug |is |calculated |to |be |the |same |as |plasma |volume, |then |
one |should |conclude |that:

A. |The |drug |has |been |eliminated |before |plasma |drug |concentration |was |measured.

B. |The |drug |did |not |leave |the |systemic |circulation.

C. |The |drug |is |present |in |the |blood |and |the |extracellular |extravascular |space |but |is |absent |
from |the |intracellular |space.

D. |The |drug |is |sequestered |to |cells |of |a |single |organ |or |to |a |specific |organelle |within |cells.

E. |None |of |the |above |- |CORRECT |ANSWER✔✔-B



The |Therapeutic |Range |of |a |drug:

A. |Is |the |range |of |plasma |concentration |of |the |drug |in |which |the |drug |produces |the |desired |
therapeutic |without |producing |any |toxic |effects |or |adverse |side |effects |also |produced.

B. |Can |only |be |determined |for |antagonist |drugs.

C. |Can |only |be |determined |for |agonist |drugs.

D. |Is |the |range |of |plasma |concentration |of |the |drug |in |which |the |drug |produces |the |desired |
therapeutic |effect |regardless |of |any |toxic |effects |or |adverse |side |effects |also |produced |- |
CORRECT |ANSWER✔✔-A



The |bioavailability |of |a |drug |administered |orally |(and |swallowed!!!) |is |0.9. |Given |this |
information, |you |conclude |that |for |an |orally |administered |dose |of |this |drug:

A. |This |drug |is |rapidly |eliminated.

B. |This |drug |is |slowly |eliminated.

C. |Most |of |an |orally |administered |dose |of |this |drug |is |absorbed |into |the |blood.

,D. |This |drug |will |likely |have |insignificant |therapeutic |benefits |if |those |benefits |require |the |drug
|to |enter |the |systemic |- |CORRECT |ANSWER✔✔-C




The |Kd |for |a |drug |is:

A. |Defined |as |the |concentration |of |drug |necessary |to |product |50% |of |the |maximum |response |
when |receptors |are |activated

B. |Defined |as |the |concentration |of |drug |at |which |50% |of |the |receptors |in |a |given |population |
will |each |be |bound |by |a |molecule |of |the |drug |(with |the |remaining |receptors |being |unoccupied
|by |drug)



C. |Defined |as |the |concentration |of |drug |required |to |inhibit |an |agonist |response |by |50% |
assuming |sufficient |agonist |s |present |to |produce |a |response |that |is |100% |of |the |maximum |
response

D. |Defined |as |the |concentration |of |drug |necessary |to |inhibit |agonist |binding |by |50% |assuming |
sufficient |agonist |is |present |to |bind |to |100% |of |the |receptors |- |CORRECT |ANSWER✔✔-B



You |are |given |the |same |oral |dose |of |a |drug |every |24 |hours. |By |the |sixth |day, |the |drug |seems |
to |have |a |reduced |effectiveness |(compared |to |its |effect |on |the |first |couple |of |days). |This |
reduced |effectiveness |could |be |the |result |of:

A. |Increased |rate |of |delivery |of |the |drug |from |the |plasma |to |its |sites |of |action |and |increased |
affinity |of |the |drug |for |the |receptors |through |which |the |response |is |induced.

B. |Increased |affinity |of |the |drug |for |the |receptors |through |which |the |response |is |induced.

C. |Increased |rate |of |delivery |of |the |drug |from |the |plasma |to |its |sites |of |action.

D. |Decreased |absorption |of |drug |from |the |gastrointestinal |tract.

E. |Decreased |rate |of |elimination |- |CORRECT |ANSWER✔✔-D



The |liver |enzyme |Enzyme |Z |metabolizes |Drug |A. |If |Drug |A |is |administered |repeatedly, |then |the
|amount |of |Enzyme |Z |in |the |liver |is |increased. |Consequently....



A. |The |rate |of |metabolism |of |Drug |A |will |not |change.

B. |The |rate |of |metabolism |of |any |drug |metabolized |by |Enzyme |Z |is |decreased.

C. |The |half-life |of |all |drugs |metabolized |by |Enzyme |Z |will |be |decreased

, D. |The |half-life |of |Drug |A |will |be |increased.

E. |The |half-life |of |Drug |B, |also |metabolized |by |Enzyme |Z, |will |not |be |affected |- |CORRECT |
ANSWER✔✔-C



When |a |drug |is |dissolved |in |an |aqueous |(water-based) |solution, |the |concentration |of |ionized |
form |of |the |drug |is |dependent |on:

A. |The |acidity |(pH) |of |the |aqueous |solution.

B. |The |lipid |solubility |of |the |drug.

C. |The |pKa |of |the |drug.

D. |The |amount |of |drug |dissolved |in |the |solution.

E. |The |acidity |(pH) |of |the |aqueous |solution, |and |the |pKa |of |the |drug, |and |the |amount |of |the |
drug |dissolved |in |the |solution |- |CORRECT |ANSWER✔✔-E



Drug |A |is |administered |repeatedly |with |a |constant |interval |between |consecutive |doses |and |
with |a |constant |dose. |The |mean |plasma |concentration |of |Drug |A |is |measured. |The |
concentration:

A. |Is |independent |on |the |route |of |administration |but |is |dependent |on |the |dose |and |the |
interval |between |consecutive |doses.

B. |Is |independent |of |the |clearance |volume |for |the |drug.

C. |Is |independent |of |the |route |of |administration

D. |Is |independent |of |the |dose |of |drug |administered |but |not |of |the |interval |between |
consecutive |doses

E. |Is |dependent |on |the |dose |and |the |interval |between |consecutive |doses |- |CORRECT |
ANSWER✔✔-E



The |therapeutic |threshold |concentration |(aka |minimal |effective |concentration) |of |a |drug:

A. |Determines |the |pharmacological |and |clinical |(or |physiological) |efficacies |of |the |drug.

B. |Is |affected |by |the |ability |of |the |body |to |eliminate |(metabolize |and/or |excrete) |the |drug |and |
depends |on |the |rate |of |absorption |of |the |drug.